-
Clinical Trial
-
Korean J Obstet Gynecol. 1998;41(10):2615-2620. Published online January 1, 2001.
- A Comparative study of Cyclophophamide and Cisplatin with or without Doxorubicin in Ovarian Carcinoma.
-
J O Kim, J W Shin, Y S Park, Y H Lee, M J Oh, J S Kang, K W Lee
-
- Abstract
- Systemic chemotherapy is the standard treatment for metastatic epithelial ovarian carcinoma. For many years, oral single-agent alkylating therapy was used, but the introduction of cisplatin in the latter half of the 1970s changed the therapeutic approach for most patients, and cisplatin-based combination chemotherapy has been the most frequently used treatment regimen in the world for the past decade. The CAP (cyclophosphamide, doxorubicin, cisplatin) regimen has been extensively used for advanced epithelial ovarian cancer. The role of additional agents, in particular doxorubicin, when used in combination chemotherapy with cisplatin, has been investigated in several large, well controlled clinical trials. No study showed a significant difference in survival. We studied retrospectively, forty seven patients with epithelial ovarian carcinoma who treated with cisplatin and cyclophosphamide (CP) versus cisplatin, cyclophosphamide, and doxorubicin (CAP) after cytoreductive surgery. The remission rates and two years survival rates were no significant difference between two groups, except cardiotoxicity of doxorubicin.
Keywords :Epithelial ovarian carcinoma;Combination chemotherapy
